The rather limited success of translation from basic research to clinical application has been highlighted as a major issue in the nanomedicine field. To identify the factors influencing the applicability of nanosystems as drug carriers and potential nanomedicine, we focused on following their fate through fluorescence-based assays, namely flow cytometry and imaging. These methods are often used to ...

Nanocarriers have brought several medical advances through better diagnostics and improved drug therapy. Yet, many promising preclinical findings were never translated into clinical success, consequently slowing drug development, and increasing its financial burden. By reliably predicting the nanoparticle fate at in vitro stages, the disappointment of suboptimal in vivo outcome could be avoided. To ...